Seres And Ferring Go Head-To-Head In Recurrent C. Difficile Market
Two New Microbiome Medicines Launched In 2023
After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.
